01前言当1980年代科学家们首次发现GLP-1（胰高血糖素样肽-1）时，很少有人能预见这个分子将在未来彻底改变现代医学。从最初作为一个血糖调节因子为人所熟知，到如今，在糖尿病、心血管疾病、阿兹海默及抑郁症、肾病和肝脏疾病、关节炎等领域都有都有所作为 ...

between dosed animals and control animals (Table 1). There were no histological signs of pancreatitis in any repeat-dose toxicity studies in rats. PCNA staining indicated cell proliferation within ...

2023年12月4日，罗氏公司花31亿美金收购Carmot公司的偏向型GLP-1的三项资产，并称其为潜在同类最佳（BIC）。自此引发国际上对此类GLP-1的高度关注 ...

Sun Pharmaceutical Industries Ltd. has divulged incretin analogues acting as dual agonists of gastric inhibitory polypeptide (GIPR) receptor/GLP-1 or GLP-1/glucagon receptor (GCGR) or triple agonists ...

2024年11月23日，先为达生物发布消息——收到国家药品监督管理局下发的《受理通知书》，公司提交的1类新药伊诺格鲁肽注射液（Ecnoglutide Injection）成人2型糖尿病患者血糖控制的适应症上市许可申请获国家药品监督管理局受理。关于伊诺格鲁肽注射液（Ecnoglutide ...

KELIX bio, wholly owned by Mubadala Investment Company, an Abu Dhabi sovereign investor, has completed the acquisition of ...

It was hard enough in the analogue era, but social media influencers ... With one in eight Americans having taken a GLP-1 already — including 43% of those with diabetes and a quarter of people ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. CagriSema induced superior weight loss compared with ...

Sciwind has granted Verdiva the exclusive global rights to develop, manufacture and commercialize the partnered programs outside of greater China and South Korea. Sciwind has retained the rights to ...

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

One in eight. That's how many people living in the United States have taken some form of a glucagon-like peptide 1, otherwise known as a GLP-1, medication for weight loss and related conditions ...